Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?

(2012) Christian Widakowich et al.   Anti-Cancer Agents in Medicinal Chemistry

Abstract 100: Preclinical and clinical studies data consolidation and federation using an integrative data analysis system: SIMUSITETM

(2011) Meena I. Vora   CANCER RESEARCH

A Message from the New Editor-in-Chief

(2010) G. C. Prendergast   CANCER RESEARCH

Downregulation of Notch Pathway by a  -Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model

(2010) C. L. Efferson et al.   CANCER RESEARCH

Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor

(2010) H. Harrison et al.   CANCER RESEARCH

Targeting Notch to Target Cancer Stem Cells

(2010) A. Pannuti et al.   CLINICAL CANCER RESEARCH

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts

(2010) Mothaffar F. Rimawi et al.   CLINICAL CANCER RESEARCH

The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches

(2010) Lara Lacerda et al.   DRUG RESISTANCE UPDATES

Chronic DLL4 blockade induces vascular neoplasms

(2010) Minhong Yan et al.   NATURE

Therapeutic antibody targeting of individual Notch receptors

(2010) Yan Wu et al.   NATURE

The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism

(2009) Raphael Kopan et al.   CELL

Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

(2009) A. Magnifico et al.   CLINICAL CANCER RESEARCH

Aromatase resistance mechanisms in model systems in vivo

(2009) Angela Brodie et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

(2009) Bella Kaufman et al.   LANCET ONCOLOGY

Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cells

(2008) Takashi Mine et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Role for Notch Signaling in Stromal Survival and Differentiation during Prostate Development

(2008) Brigid Orr et al.   ENDOCRINOLOGY

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor

(2008) C Osipo et al.   ONCOGENE